Close
  Indian J Med Microbiol
 

Figure 1: Open field locomotor recovery as assessed with BBB scoring. Weekly average BBB scores (± SEM) show a gradual recovery of hindlimb function following induction of SCI at D0. At D49, APP96-110 + nv-hMSCs (dark blue) scored significantly higher than nv-hMSCs (light blue) (*P < 0.05, Kruskal-Wallis test). There were no significant differences in average BBB score at D56 between any groups, with hMSCs and nv-hMSCs attaining a rounded average BBB score of 10, and all other groups attaining a rounded average BBB score of 11 (P > 0.05, Kruskal-Wallis test). Uninjured animals score 21. Data are expressed as the mean ± SD. Numbers of animals (n = 4–8) for each treatment group are shown in [Table 1]. APP96-110: Amyloid precursor protein peptide; BBB: Basso, Beattie, Bresnahan locomotor rating scale; hMSCs: human mesenchymal stromal cells; mAPP96-100: mutant amyloid precursor protein; nv: non-viable; SCI: spinal cord injury.

<b>Figure 1: Open field locomotor recovery as assessed with BBB scoring.</b>
Weekly average BBB scores (± SEM) show a gradual recovery of hindlimb function following induction of SCI at D0. At D49, APP96-110 + nv-hMSCs (dark blue) scored significantly higher than nv-hMSCs (light blue) (*<i>P</i> < 0.05, Kruskal-Wallis test). There were no significant differences in average BBB score at D56 between any groups, with hMSCs and nv-hMSCs attaining a rounded average BBB score of 10, and all other groups attaining a rounded average BBB score of 11 (<i>P</i> > 0.05, Kruskal-Wallis test). Uninjured animals score 21. Data are expressed as the mean ± SD. Numbers of animals (<i>n</i> = 4–8) for each treatment group are shown in [Table 1]. APP96-110: Amyloid precursor protein peptide; BBB: Basso, Beattie, Bresnahan locomotor rating scale; hMSCs: human mesenchymal stromal cells; mAPP96-100: mutant amyloid precursor protein; nv: non-viable; SCI: spinal cord injury.